PBPK, PKPD, DDI, Transporters and Human Dose Prediction explained by Novartis, Roche, Merck KGaA and GSK

Tuesday, March 21, 2017 Drug News
Email Print This Page Comment
Font : A-A+

Addressing early ADME application strategies and discussing the latest technologically advanced screen and testing models

LONDON, March 21, 2017 /PRNewswire/ -- The global ADME/TOX market is largely driven by the efforts of pharmaceutical

and biotech companies for reducing time and cost of drug discovery and ADME/Tox assays eliminate compounds with lack of bioavailability, lower efficacy and toxicity in early stages, in order to reduce time and additional expenses in the later stages of drug discovery.

This June, SMi will be presenting the 4th annual ADMET conference and exhibition in London, featuring industry specialist, discussing ADME/Tox profiling of a drug candidate and how it plays a crucial role in reducing clinical trials cost and time of drug launch to the market.

The 2017 conference agenda has been produced to offer delegates unparalleled networking opportunities, greater insight into the ADMET industry, and spotlight sessions on drug discovery strategies and PBPK modelling. Featured session not be missed will include:

Understanding PK/PD during drug discoveryRobert van Waterschoot, Head of Pharmacokinetics, Dynamics & Metabolism (PDM) Leaders, RocheIn this session Robert will explore which parameters determine the efficacious dose, whilst revisiting the free drug hypothesis.

PBPK modelling – Pragmatic application in drug developmentJackie Bloomer, Director, GSKJackie will be discussing case histories from GSK which illustrate how bespoke application of PBPK modelling can influence decision making throughout drug development.

Estimation of human volume of distribution; methods, accuracy and impact in human dose predictionCarl Petersson, Associate Director Drug Disposition, Merck KGaACarl will explore the Impact of preclinical species used for extrapolation and method comparison of accuracy and statistical significance of differences.

Drug-Drug Interactions Involving Transporters – Theory and PracticeMatthias Wittwer, Laboratory Head DMPK-BANP-NCPK, BayerMatthias will deliver a short synopsis on drug-drug interactions involving transporters with interesting examples from literature and supporting Bayer case-examples.

Delegates will also be afforded the opportunity to truly maximise their potential by attending the post-conference interactive workshop on Wednesday 14th June 2017. This additional session has been carefully structured to provide delegates with additional hands on training whilst complementing the topics of discussion covered throughout the conference.

Drug Transporter Tool KitWednesday 14th June 2017 | 08.30am - 12.30pmHosted by: Kunal Taskar, Associate GSK Fellow, GSK

For the complete 2 day agenda, visit the event website: www.admet-event.com/prlog

There is currently a £200 early bird discount for all bookings made before 31st March 2017. For more information visit www.admet-event.com/prlog

12th ADMET 201712th – 13th June 2017London, UKwww.admet-event.com/prlog  

Follow the conversation on Twitter and LinkedIn at #smiADMET17

Photo(s):https://www.prlog.org/12627811

Press release distributed by PRLog

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pbpk-pkpd-ddi-transporters-and-human-dose-prediction-explained-by-novartis-roche-merck-kgaa-and-gsk-300427052.html

SOURCE SMi Group



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook